ABSTRACT
INTRODUCTION
There are no effective treatments for COPD and new therapeutic approaches are needed as a matter of urgency. There is a strong evidence that pulmonary macrophage dysfunction plays an important role in the pathogenesis of COPD. In particular, our group has shown that pulmonary macrophages in COPD are defective in their capacity to phagocytose apoptotic airway epithelial cells (defective efferocytosis), [1] [2] [3] [4] [5] [6] which potentially contributes to the excess apoptotic material seen in the airways of these patients. This uncleared material can then potentially undergo secondary necrosis and perpetuate the inflammatory response.
The sphingolipid signalling pathway involving sphingosine kinase (SPHK) and its product sphingosine-1 phosphate (S1P) is required for effective macrophage function by promoting maturation and phagocytosis. [7] [8] [9] Recently, we identified dysregulation of the S1P signalling system as a potential cause of defective efferocytosis in alveolar macrophages in COPD. 10 Relative mRNA expression levels of several S1P system genes were increased in alveolar macrophages from COPD patients, as well as in current smokers compared with healthy non-smokers. In particular, sphingosine-1 phosphate receptor 5 (S1PR5) expression levels were significantly increased in alveolar macrophages of COPD patients independent of smoking status. 10 These findings suggested a possible link between COPD and S1PR5 function.
Genetic predisposition to COPD has been explored and these studies have in general produced inconsistent results. 11 In addition, other modulations, such as epigenetic changes, 12, 13 may also underlie the pathology of COPD. 13 Environmental stimuli, for example cigarette smoke can induce epigenetic modifications, which in turn modulate gene expression. Methylation is one of the most important epigenetic modifications of DNA. It is carried out by a family of DNA methyltransferases (DNMTs), which add methyl groups to cytosine (C) nucleotides, in particular in regions enriched in CpG dinucleotides called CpG islands. CpG islands are typically several hundred nucleotides long and are defined by at least 50% CpG content and a ratio of observed CpG to expected CpG frequency greater than 0.6. 14, 15 CpG islands are often found near gene promoters and act as gene regulatory elements. A high level of methylation at promoter-proximal CpG islands is generally associated with repression of gene transcription as it induces formation of repressive chromatin structures that hinder binding of transcription factors. [16] [17] [18] While smoking is associated with global alterations of immune and inflammatory genes in macrophages, little is known about epigenetic regulation of gene expression in alveolar macrophages in COPD. 19, 20 In this study, we investigated the DNA methylation patterns of CpG islands proximal to several S1P pathway genes in alveolar macrophages from COPD patients.
METHODS

Categorization of patients
This study was approved by the Royal Adelaide Hospital Ethics Committee (Adelaide, Australia) and informed written consent was obtained from each subject in this study. COPD was diagnosed according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) standards. Demographical details are recorded in Table 1 .
Bronchoalveolar lavage (BAL) and isolation of alveolar macrophages
Bronchoscopy was performed according to the American Thoracic Society's recommendations for the performance of bronchoscopy for investigative purposes, as previously described. 1, 8 BAL was collected then centrifuged at 1600 rpm for 5 min. Macrophages were isolated by adhering to plastic as previously described and the concentration adjusted to 4 × 10 5 cells/mL 1 then immediately snap-frozen and stored at −80 C for later use.
THP-1 culture and stimulation
THP-1 cells are a monocyte-like cell line obtained from a 1-year-old male with acute monocytic leukaemia (ATCC, Manassas, VA, USA). These cells are phagocytic and lack surface and cytoplasmic Ig. 21 THP-1 cells were cultured as described. 22 Cell cultures were maintained in a humidified atmosphere of 5% CO 2 in air at 37 C and experiments were carried out between passages 6 and 20. Differentiation of THP-1 monocytes into macrophages was induced by seeding the cells at a density of 4 × 10 5 cells/mL in 24-well plastic plates followed by stimulation with 100 nmol/L phorbol 12-myristate 13-acetate in Roswell Park Memorial Institute (RPMI) 1640 medium at 37 C with 5% CO 2 for 72 h as described. 22 The cells were rested in fresh RPMI 1640 medium at 37 C with 5% CO 2 for 24 h before being used in the experiments.
Cell stimulation
The preparation of cigarette smoke extract was carried out as previously described.
2,3,23 THP-1 macrophages were exposed to varying concentration of 5-azacytidine (Sigma-Aldrich, Sydney, Australia) with or without cigarette smoke extract for 72 h (stimulation throughout the differentiation process). Media and stimuli were refreshed every 24 h. 
Phagocytosis of apoptotic bronchial epithelial cells (efferocytosis) assay
Phagocytosis of apoptotic cells was measured as previously reported. 1, 2, 22 Briefly, stimulated/unstimulated macrophages were incubated with UV exposed 16 human bronchial epithelial (HBE) cells (apoptosis induction) at a ratio of 10:1 for 1.5 h. Subsequently, the supernatant was removed prior to 5 min incubation with cold PBS and then macrophages were gently lifted by pipetting. Lifted macrophages were then stained with CD13 phycoerythrin cyanine-7 (PE-Cy7) (BD Biosciences, San Jose, CA, USA). Trypan blue (Sigma, St. Louis, Missouri, USA) was used as autofluorescence quenching agent as reported 1, 2, 22 and up to 30 000 events were acquired immediately using a FACSCanto II Flow Cytometer (BD Biosciences). The percentage of macrophages that had ingested apoptotic cells was recorded.
Methyl quantitative real-time PCR
Genomic DNA was extracted from lung tissue macrophages using a DNA extraction kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. The concentration of the isolated DNA was determined using standard photospectrometry. Extracted genomic DNA was stored at −20 C for later use. The methyl qPCR analyses of the samples were performed using Custom EpiTect Methyl qPCR Arrays (Qiagen) in the ViiA 7 Real-Time PCR System (Life Technologies, Mulgrave, Victoria, Australia), following the manufacturer's protocol (Qiagen). The crossing threshold (C T ) value was determined for each treatment condition and then the percentage methylation for each gene-associated CpG island was calculated using the EpiTect Methyl qPCR Arrays data analysis program (Qiagen).
Bisulfite sequencing
Genomic DNA was extracted from BAL alveolar macrophages and modified by sodium bisulfite treatment using the EZ DNA Methylation-Direct Kit (Zymo Research, Irvine, CA, USA) according to the manufacturer's instructions. Bisulfite-treated DNA was used as template to amplify CpG islands in the promoter region of S1P system genes (SPHK1, S1PR1 and S1PR5) by bisulfite-specific PCR (BSP) using the ZymoTaq Premix (Zymo Research Corp, Irvine, CA, USA) master mix. Bisulfite-specific PCR primer sequences are listed in 
Statistical analysis
Statistical analysis was performed using SPSS statistic software version 22.0 (SPSS Inc.; IBM, Chicago, IL, USA). Analysis was performed using the two-sample Wilcoxon rank-sum test and the Kruskal-Wallis test for more than two groups. Bivariate correlations were determined by Pearson's correlation coefficient with significance set at P < 0.05.
RESULTS
S1PR5 gene promoter is hypomethylated in alveolar macrophages in COPD
Our previous work showed a large increase in S1PR5 mRNA expression (>14-fold) in alveolar macrophages derived from patients with COPD versus healthy non/ex-smokers. 10 We considered the possibility that this differential regulation may be epigenetically mediated.
We examined DNA methylation levels at the CpG islands of several S1P pathway genes in alveolar macrophages from COPD patients and healthy non/ex-smokers with a differential methylation of S1PR5 gene between COPD patients and controls. The S1PR5 CpG island (located over the promoter region and first exon) showed significantly decreased DNA methylation levels in alveolar macrophages from COPD subjects compared to macrophages from healthy non/ex-smokers (mean AE SEM, COPD 8.60 AE 2.53% vs controls 27.85 AE 5.48%, P < 0.05; Fig. 1A ). There were no significant differences between never-smoker and current-smoker control subjects. The S1PR5 CpG island contains 25 CpG dinucleotides (determined by MethPrimer analysis): 15 of these 25 CpG sites showed a lower level of DNA methylation in COPD patients than control subjects, with the greatest reduction at CpG site at −530 (Fig. 1B) .
Bivariate correlation analyses
Given that increased methylation is considered inhibitory to gene expression, the decreased promoter methylation is consistent with our previous observation that S1PR5 expression is higher in alveolar macrophages from COPD patients 10 and correlation analysis confirmed the negative correlation between gene expression and DNA methylation levels (r = 0.65, P < 0.05). We also found associations between S1PR5 CpG island DNA methylation levels and COPD severity (forced expiratory volume in 1 s (FEV 1 )/forced vital capacity (FVC) ratio: r = 0.32, P < 0.05; FEV 1 : r = 0.30 P < 0.05). However, no associations were found between S1PR5 CpG island 1 DNA methylation levels and smoking status, pack years, age or gender among patients with COPD.
Bioinformatic analysis of the S1PR5 CpG island
Overall, our data support the idea that S1PR5 mRNA expression is epigenetically regulated and that the differential mRNA expression of S1PR5 in COPD patients in comparison to normal controls may be in part due to differential methylation of the promoter proximal CpG island. To investigate how methylation might control S1PR5 expression, we performed bioinformatic analysis of the S1PR5 CpG island (Fig. 2) . Identification of the putative transcription factor binding sites within S1PR5 gene CpG island 1 was were found in COPD subjects relative to healthy controls (*P < 0.05 vs control) ( , controls; , COPD).
performed using the PROMO software suite that sets the matrix dissimilarity threshold of less than or equal to 15%. 26 We identified 31 consensus transcription factor binding motifs within the S1PR5 CpG island, 12 of which (EBF, ENKTF-1, TFII-I, ETF, Pax-5, p53 Sp1, GR-alpha, AP-2alphaA, E2F-1, TCF-4E, C/EBPbeta and RXR-alpha) overlapped CpG motifs. CpG site −530 that showed the greatest decrease in methylation level in COPD patients relative to healthy non/ex-smokers overlapped three transcription factor binding motifs: TFII-I, EBF and E2F-1 (Fig. 2) .
Macrophage phagocytic function is regulated by DNA methylation
If epigenetic control of specific target genes by DNA methylation is involved macrophage function/dysfunction in COPD, then experimental perturbation of methylation should alter macrophage activity. We measured the ability of THP-1 macrophages to phagocytose apoptotic bronchial epithelial cells when treated with varying concentrations of the DNA methyltransferase inhibitor 5-azacytidine (0.3 μm, 1 and 3 μmol/L). When compared to non-treated cells, THP-1 cells treated with 5-azacytidine (0.3 μm, 1 and 3 μmol/L) showed a dosedependent increase in phagocytosis (Fig. 3A) .
Cigarette smoke is a well-known cause of aberrant methylation in smokers 27, 28 and importantly is known to impair macrophage efferocytosis. [1] [2] [3] [4] [5] We therefore investigated the phagocytic ability of THP-1 macrophages cultured in the presence/absence of 10% cigarette smoke extract together with varying concentrations of 5-azacytidine (0.3 μm, 1 and 3 μmol/L). Cigarette smoke significantly decreased THP-1 macrophage phagocytic ability and this effect was inhibited by 5-azacytidine treatment at concentrations of 1 and 3 μmol/L (Fig. 3B) . Thus DNA methylation is indeed a regulator of macrophage function, at least in vitro.
DISCUSSION
We previously showed an increase in the number of apoptotic epithelial cells in the airways of COPD patients. 8 Macrophage clearance is critical before the uncleared apoptotic material undergoes secondary necrosis and induces inflammation. 8, 29 We have shown defects in macrophage phagocytic function in both COPD [1] [2] [3] [4] [5] [6] thus identification of mechanism(s)/pathways (s) that are involved in the deficient phagocytic function in COPD would potentially be an important strategy for the development of macrophage-targeted therapies.
Epigenetic regulation of gene expression has been shown to be modified in COPD. [11] [12] [13] We have previously provided evidence for a potential link between the sphingosine signalling system, in particular S1PR5 gene expression, and defective alveolar macrophage efferocytosis in COPD. 10 In the present study, we investigated the potential epigenetic regulation of this system in COPD. We found that a S1PR5 gene-associated CpG island is differentially methylated in alveolar macrophages from patients with COPD as compared to control samples. In alveolar macrophages we previously found S1PR5 expression to be higher in COPD patients versus healthy non/ex-smokers. 10 Consistent with this, we now show that S1PR5 promoter DNA methylation is lower in alveolar macrophages from COPD patients versus healthy non/ex-smokers. The fact that S1PR5 expression negatively correlates with the level of CpG island methylation suggests that methylation is an important mode of regulation for this gene. Future work will investigate the roles of potential transcription factor binding sites in S1PR5 CpG island, particularly the sites overlapping CpG −530, in regulation of S1PR5 expression. Epigenetic modifications, such as histone modification, have been reported in COPD in several studies. 11, 13 For example, histone deacetylase (HDAC) activity has been reported to be decreased in alveolar macrophages in COPD. 30, 31 Furthermore, decreased HDAC activity in response to cigarette smoke and a decrease in the ability of murine alveolar macrophages to phagocytose apoptotic neutrophils have been reported. 32 However, the study did not address phagocytosis of apoptotic cells and did not investigate human macrophages or the role of DNA methylation in efferocytosis. In this study, we found that inhibition of DNA methylation by 5-azacytidine significantly increased the efferocytosis capacity of THP-1 macrophages, suggesting a role for DNA methylation in efferocytosis. Consistent with this finding, specific DNA demethylation has been shown to favour 'M2' macrophages, 33 which are anti-inflammatory macrophages with a reduced efferocytic ability. 34 Given that cigarette smoke is the major cause of COPD, that it has been found to be associated with aberrant methylation patterns 27, 28 and that it suppresses phagocytosis, [1] [2] [3] [4] [5] [6] it is reasonable to propose that aberrant DNA methylation caused by cigarette smoke plays a role in defective efferocytosis. Consistent with this proposal, we found that global DNA demethylation by 5-azacytidine in THP-1 macrophages, rescued these cells from suppressed efferocytosis in response to cigarette smoke. Further studies are required to determine whether modulation of S1PR5 or other genes within the S1P pathway are involved in this functional rescue. Others have also reported a link between cigarette smoke, defective efferocytosis and epigenetic modification in alveolar macrophages: Noda et al. showed that cigarette smoke decreased HDAC activity and macrophage efferocytosis via inhibition of HDAC/Rac/CD9 pathway. 32 By providing new evidence that DNA methylation controls macrophage function and showing that a key component of the S1P pathway is differentially regulated by DNA methylation in macrophages in COPD, our study further strengthens the links between epigenetic regulation, macrophage dysfunction and COPD.
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